Back to results
US 2003/0083318 A1Published application
Therapy for neurodegenerative diseases
OwnerJean-Pierre Julien, Jasna Krizinventors
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerJean-Pierre Julien, Jasna Krizinventors
Estimating the term…
The present invention relates to a method for reducing symptoms related to a neurodegenerative disease and/or treating a neurodegenerative disease, this therapy comprising the administration of a therapeutically effective amount of at least two compounds selected from the group of an inhibitor of microglial activation, an antiglutominergic agent and a voltage gated calcium channer blocker to a patient suffering from a neurodegenerative disease. The present invention also relates to a composition for reducing symptoms related to a neurodegenerative disease and/or treating a neurodegenerative disease, comprising a therapeutically effective amount of at least two compounds selected from the group of an inhibitor of microglial activation, an antiglutaminergic agent and a voltage gated calcium channel blocker in association with a pharmaceutically acceptable carrier.
A method for reducing symptoms related to a neurodegenerative disease and/or treating said neurodegenerative disease, said therapy comprising the administration of a therapeutically effective amount of at least two compounds selected from the group of an inhibitor of microglial activation, an antiglutominergic agent and a voltage gated calcium channer blocker to a patient suffering from said neurodegenerative disease.
A composition for reducing symptoms related to a neurodegenerative disease and/or treating said neurodegenerative disease, comprising a therapeutically effective amount of at least two compounds selected from the group of an inhibitor of microglial activation, an antiglutaminergic agent and a voltage gated calcium channel blocker in association with a pharmaceutically acceptable carrier.
A composition for reducing symptoms related to a neurodegenerative disease and/or treating said neurodegenerative disease, comprising a therapeutically effective amount of at least two compounds selected from the group of an inhibitor of microglial activation, an antiglutaminergic agent and a voltage gated calcium channel blocker, wherein said inhibitor of microglial activation, said antiglutaminergic agent and said voltage gated calcium channel blocker being administered in association with a pharmaceutically acceptable carrier to a subject simultaneously or consecutively.
Dependencies are inferred from the claim text.